We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
| Characteristics | Description |
|---|---|
| Input/Output | 5V DC, 1A |
| Type | USB-A to USB micro-B |
| Length | 36 inches (91 cm) |


Yes, insurance may cover both the product (sensor and transmitter) and the insertion and removal procedures. However every situation is different, so we recommend you get in touch via our pre-qualify form and an Eversense Expert can confirm what insurance covers for you and what out-of-pocket costs you may have.
Eversense gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by a healthcare professional. The smart transmitter sits above the sensor, sending glucose data to your app. Want to learn more about the science behind Eversense? Check out our “How Eversense Works” video!
Eversense® E3 is not indicated for use in children.
Eversense® E3 is a continuous glucose monitoring system indicated for the management of diabetes in adults age 18 years and older.
If you do not have access to a blood glucose meter when you receive a calibration prompt, your Eversense E3 CGM system will continue to provide glucose readings for up to 4 additional hours. You should take action during this time to obtain your blood glucose meter. After the 4 hours, you will receive a Calibration Past Due alert and no glucose values will be displayed until the next calibration is entered.

Even with a non-adjunctive CGM system, you should always carry a blood glucose meter with you as you should always be prepared to take a blood glucose test when prompted for a calibration or when any of the following situations occur:
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060